Clinical trials: Endometrial Cancer, open to volunteers
Ovarian Cancer, Endometrial Cancer
Proactive Immune Tolerance Induction in Chemotherapy for Gynecologic Cancer
The goal of this clinical trial is to evaluate the efficacy of proactive immune tolerance induction of chemotherapy (paclitaxel and carboplatin) for patients with gynecologic cancer.
- Conditions
- Ovarian Cancer, Endometrial Cancer, Cervical Cancer
- Trial name
- NCT06977594
- Testing
- Proactive immune tolerance induction, Standard Treatment, Paclitaxel and carboplatin
- Where
- South Korea
- Volunteers
- 1,000 people
- Sponsor
- Seoul National University Hospital
Endometrial Cancer
Prevalence of Germline Alterations in Actionable Genes in Endometrial Cancer
Endometrial cancer (EC) is the most common gynecological cancer in developed countries, with 10200 new cases of EC (5.5% of all cancers) estimated in 2023 and 2500 death for EC estimated in 2022 in Italy.
- Trial name
- GerEC (NCT07066969)
- Testing
- Sophia DDM
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- European Institute of Oncology
Neoplasms, Endometrial
A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC)
The goal of this study is to evaluate the safety profile of dostarlimab in Indian adults with recurrent or advanced endometrial cancer.
- Trial name
- NCT06897527
- Testing
- Dostarlimab
- Volunteers
- 100 people
- Sponsor
- GlaxoSmithKline
Ovarian Cancer, Small Cell Lung Cancer
A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation
This is a first-in-human, Phase 1/2, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of LG00313112 in participants with advanced solid malignancies harboring a TP53 Y220C…
- Conditions
- Ovarian Cancer, Small Cell Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer
- Trial name
- NCT07752875
- Testing
- LG00313112
- Volunteers
- 250 people
- Sponsor
- LG Chem
Endometrial Adenocarcinoma, Metastatic Endometrial Cancer
Assessing Survival Outcomes With Checkpoint Inhibition ExteNded vs Discontinued in Endometrial Cancer
This is a pragmatic, non-inferiority randomized hybrid decentralized clinical trial. The goal of this study is to determine if one year of maintenance immunotherapy (anti-PD1 agent therapy; pembrolizumab or dostarlimab) is…
- Conditions
- Endometrial Adenocarcinoma, Metastatic Endometrial Cancer, Endometrial Cancer, Recurrent Endometrial Cancer
- Trial name
- ASCEND-EC-DCT (NCT07867002)
- Testing
- anti-PD1 agent therapy - 1 year, anti-PD1 agent therapy - 2 years
- Where
- 6 sites in United States
- Volunteers
- 140 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Prostate Cancer, Hepatocellular Carcinoma
68Ga-FAPI-PSMA PET Imaging for the Diagnosis of Solid Tumors
This study aims to evaluate a novel dual-targeted PET imaging tracer, 68Ga-FAPI-PSMA, for the detection and evaluation of solid tumors.
- Conditions
- Prostate Cancer, Hepatocellular Carcinoma, Ovarian Cancer, Solid Tumors
- Trial name
- NCT07639801
- Testing
- 68Ga-FAPI-PSMA, 68Ga-PSMA-617, 68Ga-FAPI-04
- Volunteers
- 20 people
- Sponsor
- Peking University Cancer Hospital & Institute
Endometrial Cancer
ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancer
The researchers are doing this study to evaluate the use of circulating tumor DNA (ctDNA) testing in making treatment decisions for advanced/recurrent endometrial cancer that has a change (mutation) in the mismatch repair…
- Trial name
- NCT07270666
- Testing
- ctDNA Testing, Blood draw, Surveys
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Platinum-resistant Ovarian Cancer, Testicular Cancer
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 (study drug), a CLDN6-directed T cell-engaging bispecific antibody , in participants with…
- Conditions
- Platinum-resistant Ovarian Cancer, Testicular Cancer, Endometrial Cancer
- Trial name
- NCT06515613
- Testing
- CTIM-76
- Where
- 15 sites in United States, United Kingdom
- Volunteers
- 156 people
- Sponsor
- Context Therapeutics Inc.
Endometrial Cancer
a SIngle Center Study of Post-operative STEReotactic RAdiotherapY for Endometrial Cancer
The primary endpoint of the present prospective study is to assess the outcomes in terms of acute toxicity of post-operative stereotactic radiotherapy for endometrial cancer
- Trial name
- SISTER-RAY (NCT06360653)
- Testing
- Stereotactic Post-operative Radiotherapy for Endometrial Cancer
- Where
- 2 sites in Italy
- Volunteers
- 60 people
- Sponsor
- ARNAS Civico Di Cristina Benfratelli Hospital
Endometrial Cancer, Cervix Cancer
Postoperative Hypofractionated Whole Pelvic Radiotherapy in Cervical and Endometrial Cancer
This study aims to evaluate a shorter course of postoperative pelvic radiotherapy in patients with cervical and endometrial cancer.
- Trial name
- PostOP HYPOCxE (NCT07595224)
- Testing
- Hypofractionated Radiotherapy, Conventional Radiotherapy
- Where
- Thailand
- Volunteers
- 120 people
- Sponsor
- Siriraj Hospital
Biliary Tract Cancer, Breast Cancer
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
- Conditions
- Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer
- Trial name
- NCT06239194
- Testing
- MDX2001
- Where
- 6 sites in United States
- Volunteers
- 330 people
- Sponsor
- ModeX Therapeutics, An OPKO Health Company
Ovarian Cancer, Malignant Neoplasm of Uterus
Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer
This is an open-label, Phase 1 study with a dose expansion cohort of Sacituzumab Govitecan in Combination with Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer.
- Trial name
- NCT06040970
- Testing
- Sacituzumab, Cisplatin
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer
This phase II trial studies whether adding tirzepatide injections to a levonorgestrel intrauterine device (LNG-IUD) improves pathologic response (absence of cancer cells in tissue samples after treatment) in women with…
- Trial name
- NCT07349641
- Testing
- Medical Device Usage and Evaluation, Tirzepatide
- Where
- 3 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Cancer, Endometrial Cancer
Adaptive Radiotherapy for Safe Hypofractionation
This phase II, registry-based cohort-multiple randomized controlled trial (cmRCT) evaluates whether daily online adaptive radiotherapy (ART) enables the safe delivery of hypofractionated, iso-biologically equivalent (EQD2)…
- Conditions
- Cancer, Endometrial Cancer, Prostate Cancer, Cervical Cancer
- Trial name
- ART-Hypo (NCT07516210)
- Testing
- Adaptive Hypofractionated Radiotherapy, Standard-of-care Radiotherapy
- Where
- Canada
- Volunteers
- 264 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Cervical Cancer, Endometrial Cancer
MH-ART vs CF-IMRT in Postoperative Cervical/Endometrial Cancer
This is an investigator-initiated, prospective, national multi-center, phase III, randomized, open-label, non-inferiority clinical study.
- Trial name
- ARTISAN (NCT07584161)
- Testing
- Moderately fractionated radiotherapy using online adaptive radiotherapy technology, Conventionally fractionated radiotherapy using image-guided intensity-modulated radiotherapy technology.
- Where
- China
- Volunteers
- 228 people
- Sponsor
- Xiaorong Hou
Breast Neoplasms, Colorectal Neoplasms
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
The main purpose of this study is to evaluate safety, tolerability, and efficacy of LY4257496 alone and as part of relevant standard of care (SOC) combination therapy in participants with Gastrin-releasing Peptide Receptor…
- Conditions
- Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms
- Trial name
- OMNIRAY (NCT07114601)
- Testing
- LY4257496, Standard of Care Anticancer Therapies, LY4257529
- Where
- 33 sites in United States, Canada and 5 more
- Volunteers
- 421 people
- Sponsor
- Eli Lilly and Company
Endometrial Carcinoma, TP53 Mutation
Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
This study is an open-label Phase II randomized controlled trial designed to evaluate the safety and efficacy of camrelizumab plus fluzoparib maintenance therapy in patients with recurrent or metastatic TP-53 mutated Endometrial…
- Conditions
- Endometrial Carcinoma, TP53 Mutation, Recurrent or Metastatic
- Trial name
- NCT06413992
- Testing
- Fluzoparib, Camrelizumab, paclitaxel (albumin bound)
- Where
- China
- Volunteers
- 117 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Carcinoma, Endometrioid, Fertility Preservation
Fertility Sparing Therapy for Patients With Stage IA G2 Endometrial Cancer
Endometrial cancer (EC) is a prevalent gynecological cancer with an escalating global incidence and a decreasing age of onset. In the era of precision medicine, there is an increasing emphasis on tailoring treatments to different…
- Trial name
- NCT06468215
- Testing
- Treatment Option 1 is a single-drug regimen, with oral medroxyprogesterone acetate (MPA) 500mg/d or MA 320mg/d.
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Peking University People's Hospital
Breast Cancer, Endometrial Cancer
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway…
- Conditions
- Breast Cancer, Endometrial Cancer, Ovarian Cancer, Lung Squamous Cell Carcinoma
- Trial name
- NCT07109726
- Testing
- TER-2013, Fulvestrant injection
- Where
- 20 sites in United States, Portugal and 2 more
- Volunteers
- 205 people
- Sponsor
- Terremoto Biosciences Inc.
Endometrial Cancer
Modality of Adjuvant Radiotherapy and Chemotherapy for Stage Ⅲ Endometrial Cancer
Endometrial cancer is the most common gynecological malignancy affecting women's health. About 15% of the patients will have local late disease (stage III) with high risk of recurrence and tumor related mortality.
- Trial name
- NCT04453904
- Testing
- sequential radiochemotherapy in a "sanwich" mode
- Where
- China
- Volunteers
- 654 people
- Sponsor
- Peking University People's Hospital